Table 1.
Baseline characteristics stratified by the occurrence of the primary endpoint events
| Overall (n = 4530) | Non-events (n = 4389) |
Events (n = 141) |
P value | |
|---|---|---|---|---|
| Age, years | 59.53 ± 10.02 | 59.37 ± 9.95 | 64.63 ± 10.89 | < 0.001 |
| Male | 3525 (77.8) | 3417 (77.9) | 108 (76.6) | 0.802 |
| BMI, kg/m2 | 25.89 ± 3.18 | 25.91 ± 3.18 | 25.27 ± 3.15 | 0.019 |
| DM | 1951 (43.1) | 1877 (42.8) | 74 (52.5) | 0.027 |
| Hypertension | 2866 (63.3) | 2768 (63.1) | 98 (69.5) | 0.141 |
| SBP, mmHg | 130.53 ± 17.66 | 130.38 ± 17.57 | 135.20 ± 19.85 | 0.001 |
| DBP, mmHg | 77.28 ± 10.93 | 77.32 ± 10.92 | 76.16 ± 11.43 | 0.217 |
| Current smoker | 1447 (31.9) | 1406 (32.0) | 41 (29.1) | 0.516 |
| ACS | 2813 (62.1) | 2734 (62.3) | 79 (56.0) | 0.155 |
| Family history of CAD | 562 (12.4) | 544 (12.4) | 18 (12.8) | 0.998 |
| Previous MI | 1035 (22.8) | 988 (22.5) | 47 (33.3) | 0.004 |
| Previous PCI | 896 (19.8) | 859 (19.6) | 37 (26.2) | 0.064 |
| Previous CABG | 52 (1.1) | 51 (1.2) | 1 (0.7) | 0.924 |
| Previous stroke | 582 (12.8) | 557 (12.7) | 25 (17.7) | 0.103 |
| Previous PAD | 260 (5.7) | 245 (5.6) | 15 (10.6) | 0.018 |
| CKD | 90 (2.0) | 76 (1.7) | 14 (9.9) | < 0.001 |
| LVEF, % | 62.56 ± 5.11 | 62.61 ± 4.97 | 60.98 ± 8.20 | < 0.001 |
| Laboratory results | ||||
| TyG | 8.90 ± 0.57 | 8.89 ± 0.56 | 9.10 ± 0.66 | < 0.001 |
| FBG, mmol/L | 6.46 ± 2.32 | 6.41 ± 2.24 | 7.81 ± 3.86 | < 0.001 |
| HbA1c, % | 6.43 ± 1.21 | 6.41 ± 1.20 | 6.80 ± 1.47 | < 0.001 |
| TC, mmol/L | 4.01 ± 1.03 | 4.00 ± 1.02 | 4.09 ± 1.12 | 0.323 |
| TG, mmol/L | 1.66 ± 0.82 | 1.66 ± 0.82 | 1.72 ± 0.80 | 0.177 |
| LDL-C, mmol/L | 2.41 ± 0.88 | 2.41 ± 0.88 | 2.49 ± 0.99 | 0.291 |
| HDL-C, mmol/L | 1.10 ± 0.30 | 1.10 ± 0.30 | 1.08 ± 0.36 | 0.356 |
| hsCRP, mg/L | 2.67 ± 3.07 | 2.65 ± 3.06 | 3.20 ± 3.33 | 0.006 |
| Creatinine, µmol/L | 82.92 ± 21.16 | 82.64 ± 20.80 | 91.43 ± 28.94 | < 0.001 |
| Lipoprotein(a), mg/L | 30.42 ± 30.64 | 30.47 ± 30.66 | 28.92 ± 30.28 | 0.469 |
| Medications | ||||
| Clopidogrel | 3860 (85.2) | 3736 (85.1) | 124 (87.9) | 0.419 |
| ACEI/ARB | 1170 (25.8) | 1134 (25.8) | 36 (25.5) | 1.000 |
| β-blocker | 3994 (88.2) | 3869 (88.2) | 125 (88.7) | 0.961 |
| CCB | 1634 (36.1) | 1577 (35.9) | 57 (40.4) | 0.315 |
| Statins | 4383 (96.8) | 4246 (96.7) | 137 (97.2) | 0.971 |
| Antidiabetic drugs | 1514 (33.4) | 1455 (33.2) | 59 (41.8) | 0.039 |
| Nitrate | 4391 (96.9) | 4257 (97.0) | 134 (95.0) | 0.281 |
| Angiographic findings | ||||
| SYNTAX score | 15.53 ± 5.76 | 15.51 ± 5.74 | 16.04 ± 6.54 | 0.507 |
| Left main disease | 532 (11.7) | 512 (11.7) | 20 (14.2) | 0.434 |
| three-vessel disease | 1870 (41.3) | 1799 (41.0) | 71 (50.4) | 0.033 |
| Chronic total occlusion | 392 (8.7) | 374 (8.5) | 18 (12.8) | 0.107 |
| Type B2/C lesion | 3811 (84.1) | 3690 (84.1) | 121 (85.8) | 0.660 |
| Ostial lesions | 1060 (23.4) | 1029 (23.4) | 31 (22.0) | 0.763 |
| Thrombotic lesions | 59 (1.3) | 57 (1.3) | 2 (1.4) | 1.000 |
| Severe calcification | 153 (3.4) | 145 (3.3) | 8 (5.7) | 0.195 |
Values are presented as mean ± standard deviation or number (%). ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; FBG, fasting blood glucose; HbA1c, Hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; SYNTAX, synergy between PCI with taxus and cardiac surgery; TC, total cholesterol; TG, triglyceride; TyG, triglyceride-glucose